MSN Life Sciences is an API and finished-dose manufacturer based in India. It holds 160 active US drug master files and 48 valid CEPs. Its filings concentrate with ARCSA (EC), CDSCO (India) and MINSA (CR). Its GMP standing is certified by MFDS (Korea), EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 13 September 2024 as VAI. Customs aggregates show $9.6M of exports covering 198 molecules to 34 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Chandampet Village, India | Not on file |
| Kamareddy, India | Not on file |
| Bhiknoor Village, India | Not on file |
| Medak, India | Not on file |
| Medak District, India | 3011543392 |
| Kamareddy District, India | 3014775167 |
| Molecule | Regulators | Docs |
|---|---|---|
| Esomeprazole | EDQM, SFDA (Saudi Arabia), US FDA | 7 |
| Sacubitril | SFDA (Saudi Arabia), US FDA | 6 |
| Sitagliptin | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Apremilast | US FDA | 4 |
| Macitentan | SFDA (Saudi Arabia), US FDA | 4 |
| Mebendazole | EDQM, US FDA | 4 |
| Metoprolol | EDQM, US FDA | 4 |
| Pirfenidone | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Riociguat | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Darunavir | SFDA (Saudi Arabia), US FDA | 3 |
| Empagliflozin | SFDA (Saudi Arabia), US FDA | 3 |
| Haloperidol | EDQM, US FDA | 3 |
| Levetiracetam | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Losartan | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Albendazole | EDQM, US FDA | 2 |
| Atorvastatin | SFDA (Saudi Arabia), US FDA | 2 |
| Bupivacaine | EDQM, US FDA | 2 |
| Canagliflozin | US FDA | 2 |
| Caspofungin | SFDA (Saudi Arabia), US FDA | 2 |
| Clobazam | EDQM, US FDA | 2 |
| Clopidogrel | US FDA | 2 |
| Desvenlafaxine | US FDA | 2 |
| Dolutegravir | US FDA | 2 |
| Doxepin | EDQM, US FDA | 2 |
| Elvitegravir | US FDA | 2 |
| Famotidine | EDQM, US FDA | 2 |
| Flecainide | EDQM, US FDA | 2 |
| Fluphenazine | US FDA | 2 |
| Gadobutrol | EDQM, US FDA | 2 |
| Glimepiride | EDQM, US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| ARCSA (EC) | 45 | None |
| CDSCO (India) | 22 | None |
| MINSA (CR) | 9 | None |
| INVIMA (CO) | 8 | None |
| MFDS (Korea) | None | 2 |
| EMA | None | 2 |
| US FDA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $8.0M | 30 |
| 2025 | Not reported | $9.6M | 34 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. MSN Life Sciences comes back tiered against every other supplier able to file there.
Start for free